|
PVRL3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.73460176514595E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.64629999527466E-08 |
| Normal-vs-Stage2 |
2.623600E-04 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.45040002230701E-09 |
| Stage1-vs-Stage2 |
9.380800E-01 |
| Stage1-vs-Stage3 |
3.55459999999974E-05 |
| Stage1-vs-Stage4 |
2.598000E-02 |
| Stage2-vs-Stage3 |
1.545700E-02 |
| Stage2-vs-Stage4 |
6.472100E-02 |
| Stage3-vs-Stage4 |
7.851800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.86801701779405E-13 |
| Normal-vs-AfricanAmerican |
4.522400E-02 |
| Normal-vs-Asian |
1.657740E-02 |
| Caucasian-vs-AfricanAmerican |
1.012600E-01 |
| Caucasian-vs-Asian |
7.479700E-03 |
| AfricanAmerican-vs-Asian |
8.230400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.45480000163434E-09 |
| Normal-vs-Female |
1.67760028091379E-10 |
| Male-vs-Female |
6.246400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.17349999995131E-06 |
| Normal-vs-Age(41-60Yrs) |
1.50790047115379E-10 |
| Normal-vs-Age(61-80Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(81-100Yrs) |
4.38999999999856E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.129030E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.374800E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.158800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.709800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.468400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.179600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.84263715397037E-12 |
| Classical-VS-Follicular |
2.634300E-02 |
| Classical-VS-Other |
3.103000E-01 |
| Classical-VS-Normal |
7.03319957828796E-10 |
| Tall-VS-Follicular |
6.23779916608669E-11 |
| Tall-VS-Other |
2.483600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.119040E-01 |
| Follicular-VS-Normal |
5.788400E-04 |
| Other-VS-Normal |
1.243490E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.04870001571555E-09 |
| Normal-vs-N1 |
7.17530479477091E-11 |
| N0-vs-N1 |
8.894400E-02 |
|
|
